---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-020309"
form_type: "8-K"
ticker: "SONM"
cik: "0001178697"
company_name: "DNA X, Inc."
filed_at: "2025-10-31T23:59:59+00:00"
generated_at: "2026-05-17T01:04:08.677272+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sonim Q3 revenue $16.2M (+45% seq), net loss narrows to $4.8M; asset sale to NEXA for $15M on track for Q4 close

## Summary
- Net revenue $16.2M, up 45% sequentially from Q2; GAAP net loss $4.8M vs $7.5M in Q2.
- Adjusted EBITDA negative $2.0M, improving from negative $3.2M in Q2.
- Entered definitive agreement to sell substantially all assets to NEXA for $15M cash plus up to $5M earn-out; expected close late Q4 2025.
- Reverse stock split 1-for-18 effected Oct 27, 2025 to regain Nasdaq compliance.
- Cash $2.1M; received $4.8M net proceeds from equity offerings during Q3.

## SEC filing metadata
- accession: 0001493152-25-020309
- form_type: 8-K
- ticker: SONM
- cik: 0001178697
- company_name: DNA X, Inc.
- filed_at: 2025-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178697/000149315225020309/0001493152-25-020309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178697/000149315225020309/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-020309
- JSON: https://secwatch.observer/filing/0001493152-25-020309.json
- Plain text: https://secwatch.observer/filing/0001493152-25-020309.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.